A Phase IIb, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Basmisanil (RO5186582) as Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia Treated With Antipsychotics
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Basmisanil (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Roche
- 16 Mar 2017 Planned End Date changed from 1 Sep 2018 to 23 Aug 2018.
- 16 Mar 2017 Planned primary completion date changed from 1 Sep 2018 to 23 Aug 2018.
- 16 Mar 2017 Status changed from not yet recruiting to recruiting.